KORU Medical posts investor presentation on large-volume subcutaneous drug delivery growth strategy

KORU Medical Systems, Inc.

KRMD

0.00

KORU Medical outlined a strategy to expand its Freedom Infusion System beyond subcutaneous immunoglobulin into large-volume subcutaneous therapies.
FY2025 revenue USD 41.1 million, up 22% year over year; guidance reiterated at USD 47.5 million to USD 50 million for 2026.
1Q 2026 revenue USD 11.8 million; gross margin 61.5%; net loss narrowed to USD 0.8 million; cash usage USD 0.1 million.
Installed base of about 60,000 patients, supporting 2.7 million annual infusions; about 75% of revenue described as recurring.
Management transition set for July 1, 2026, with Adam Kalbermatten to become CEO as Linda Tharby retires.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KORU Medical Systems Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.